Conformational behavior of human α-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T

NeuroToxicology

Volumn 23, Issue 4-5, 2002, Pages 553-567

  Li, Jie ^a   Uversky, Vladimir N ^a,b   Fink, Anthony L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUTE FOR BIOLOGICAL INSTRUMENTATION   (Russian Federation)

Author keywords

Synuclein; Aggregation; Familial Parkinson's disease point mutations; Fibrillation; Heparin; Parkinson's disease; Partially folded intermediate; Pesticides

Indexed keywords

ALPHA SYNUCLEIN; DIETHYLDITHIOCARBAMIC ACID; HEPARIN; PESTICIDE; THIOFLAVINE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; NERVE PROTEIN; SNCA PROTEIN, HUMAN; SYNUCLEIN;

CIRCULAR DICHROISM; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONFORMATIONAL TRANSITION; FAMILIAL DISEASE; FLUORESCENCE; HIGH TEMPERATURE; HUMAN; LIGHT SCATTERING; NONHUMAN; PARKINSON DISEASE; PH; POINT MUTATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; ULTRAVIOLET RADIATION; ALGORITHM; ARTICLE; CHEMISTRY; GENETICS; INFRARED SPECTROSCOPY; ISOLATION AND PURIFICATION; KINETICS; METABOLISM; PROTEIN CONFORMATION; RADIATION SCATTERING; SPECTROFLUOROMETRY; X RAY;

ALGORITHMS; ALPHA-SYNUCLEIN; CIRCULAR DICHROISM; HUMANS; INDICATORS AND REAGENTS; KINETICS; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PESTICIDES; POINT MUTATION; PROTEIN CONFORMATION; PROTEIN FOLDING; SCATTERING, RADIATION; SPECTROMETRY, FLUORESCENCE; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SYNUCLEINS; X-RAYS;

EID: 0036777533     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-813X(02)00066-9     Document Type: Conference Paper

References (62)

1. Altschuler E. Aluminum-containing antacids as a cause of idiopathic Parkinson's disease. Med Hypotheses 1999;53:22-3.
2. Clayton DF, George JM. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci 1998;21:249-54.
3. Clark AH, Saunderson DH, Suggett A. Infrared and laser-Raman spectroscopic studies of thermally-induced globular protein gels. Int J Pept Prot Res 1981;17:353-64.
4. Cohlberg JA, Li J, Uversky VN, Fink AL. Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from α-synuclein in vitro. Biochemistry 2001;40.
5. Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 1998;4:1318-20.
6. Conway KA, Harper JD, Lansbury PT. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 2000a;39:2552-63.
7. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 2000b;97:571-6.
8. Crowther RA, Jakes R, Spillantini MG, Goedert M. Synthetic filaments assembled from C-terminally truncated alphasynuclein. FEBS Lett 1998;436:309-12.
9. Duffy PE, Tennson VM. J Nerophathol Exp Neurol 1965;24:398-414.
10. Duvoisin RC. A brief history of Parkinsonism. Neurol Clin 1992;10:310-6.
11. El-Agnaf OMA, Jakes R, Curran MD, Wallace A. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease. FEBS Lett 1998;440:67-70.
12. Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature 2000;404:394-8.
13. Fink AL. Protein aggregation: folding aggregates, inclusion bodies and amyloid. Fold Design 1998;3:9-15.
14. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996;55:259-72.
15. George JM, Jin H, Wood WS, Clayton DF. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 1995;15:361-72.
16. Giasson BI, Uryu K, Trojanowski JQ, Lee VM. Mutant and wildtype human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem 1999;274:7619-22.
17. Glatter O, Kratky O. Small angle X-ray scattering. New York: Academic Press, 1982.
18. Goedert M. Familial Parkinson's disease: the awakening of alpha-synuclein. Nature (Lond) 1997;388:232-3.
19. Good PF, Olanow CW, Perl DP. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res 1992;593:343-6.
20. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Kortsha GX, Brown GG, Richardson RJ. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology 1999;20:239-47.
21. Gourie-Devi M, Ramu MG, Venkataram BS. Treatment of Parkinson's disease in 'Ayurveda' (ancient Indian system of medicine): discussion paper. J R Soc Med 1991;84:491-2.
22. Hertzman C, Wiens M, Snow B, Kelly S, Calne D. A case-control study of Parkinson's disease in a horticultural region of British Columbia. Mov Disord 1994;9:69-75.
23. Hirsch EC, Brandel JP, Galle P, Javoy-Agid F, Agid Y. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J Neurochem 1991;56:446-51.
24. Hsu LJ, Mallory M, Xia Y, Veinbergs I, Hashimoto M, Yoshimoto M, Thal LJ, Saitoh T, Masliah E. Expression pattern of synucleins (non-Abeta component of Alzheimer's disease amyloid precursor protein/alpha-synuclein) during murine brain development. J Neurochem 1998;71:338-44.
25. Ismail AA, Mantsch HH, Wong PTT. Aggregation of chymotrypsinogen: portrait by infrared spectroscopy. Biochim Biophys Acta 1992;1121:183-8.
26. Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A, Saitoh T. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995;14:467-75.
27. Jakes R, Spillantini MG, Goedert M. Identification of two distinct synucleins from human brain. FBS Lett 1994;345:27-32.
28. Kendrick BS, Cleland JL, Lam X, Nguyen T, Randolph TW, Manning MC, Carpenter JF. Aggregation of recombinant human interferon gamma: kinetics and structural transitions. J Pharm Sci 1998;87:1069-76.
29. Krüger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998;18:106-8.
30. Le Couteur DG, McLean AJ, Taylor MC, Woodham BL, Board PG. Pesticides and Parkinson's disease. Biomed Pharmacother 1999;53:122-30.
31. Lewy FH. Paralysis Agitans. Pathologische Anatomie. In: Lewandowski M, editor. Handbuch der Neurologie. Berlin: Springer, 1912. p. 920-33.
32. Li J, Uversky VN, Fink AL. Effect of familial Parkinson's disease point mutations A30P and A53T on structural properties, "stability", aggregation and fibrillation capability of human αsynuclein. Biochemistry 2001;40:11604-13.
33. Manning-Bog AB, McCormack AL, Li J, Uversky VN, Fink AL, Di Monte DA. The herbicide paraquate causes upregulation and aggregation of α-synuclein in mice. J Biol Chem 2001;276.
34. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000;287:1265-9.
35. Maroteaux L, Campanelli JT, Scheller RH. Synuclein: a neuronspecific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 1988;8:2804-15.
36. Naiki H, Higuchi K, Hosokawa M, Takeda T. Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, Thioflavin Tx. Anal Biochem 1989;177:244-9.
37. Naiki H, Higuchi K, Matsushima K, Shimada A, Chen WH, Hosokawa M, Takeda T. Fluorometric examination of tissue amyloid fibrils in murine senile amyloidosis: use of the fluorescent indicator, thioflavine T. Lab Invest 1990;62:768-73.
38. Narhi L, Wood SJ, Steavenson S, Jiang Y, Wu GM, Anafi D, Kaufman SA, Martin F, Sitney K, Denis P, Louis JC, Wypych J, Biere AL, Citron M. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J Biol Chem 1999;274:9843-6.
39. Nielsen L, Khurana R, Coats A, Frokjaer S, Brange J, Vyas S, Uversky VN, Fink AL. Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. Biochemistry 2001a;40:6036-46.
40. Nielsen L, Frokjaer S, Carpenter JF, Brange J. Studies of the structure of insulin fibrils by Fourier transform infrared (FTIR) spectroscopy and electron microscopy. J Pharm Sci 2001b;90:29-37.
41. Oberg KA, Fink AL. A new attenuated total reflectance Fourier transform infrared spectroscopy method for the study of proteins in solution. Anal Biochem 1998;256:92-106.
42. Oberg K, Chrunyk BA, Wetzel R, Fink AL. Nativelike secondary structure in interleukin-1 beta inclusion bodies by attenuated total reflectance FTIR. Biochemistry 1994;33:2628-34.
43. Okazaki H, Lipkin LE, Aronson SM. J Nerophathol Exp Neurol 1961;21:442-9.
44. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-7.
45. Przybycien TM, Dunn JP, Valax P, Georgiou G. Secondary structure characterization of beta-lactamase inclusion bodies. Protein Eng 1994;7:131-6.
46. Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci USA 2000;97:4897-902.
47. Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature (Lond) 1997;388:839-40.
48. Spillantini MG, Growther RA, Jakes R, Hasegawa M, Goedert M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci USA 1998;95:6469-73.
49. Tanner CM. The role of environmental toxins in the etiology of Parkinson's disease. Trends Neurosci 1989;2:49-54.
50. Trojanowski JQ, Goedert M, Iwatsubo T, Lee VM-Y. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death Diff 1998;5:832-7.
51. Tsuruta H, Brennan S, Rek ZU, Irving TC, Tompkins WH, Hodgson KO. A wide-bandpass multilayer monochromator for biological small-angle scattering and fiber diffraction studies. J Appl Cryst 1998;31:672-82.
52. Uversky VN, Segel DJ, Doniach S, Fink AL. Association-induced folding in globular proteins. Proc Natl Acad Sci USA 1998;95:5480-3.
53. Uversky VN, Khurana R, Karnoup AS, Segel D, Doniach S, Fink AL. Association of partially-folded intermediates of Staphylococcal nuclease induces structure and stability. Protein Sci 1999;8:161-73.
54. Uversky VN, Gillespie JR, Fink AL. Why are "natively unfolded" proteins unstructured under the physiological conditions? Proteins Struct Funct Genet 2000;42:327-415.
55. Uversky VN, Li J, Fink AL. Evidence for a partially-folded intermediate in α-synuclein fibrillation. J Biol Chem 2001a;676:10737-44.
56. Uversky VN, Li J, Fink AL. Pesticides directly accelerate the rate of α-synuclein fibril formation: a possible factor in Parkinson's disease. FEBS Lett 2001b;500:105-8.
57. Uversky VN, Li J, Fink AL. Metal-triggered structural transformations, aggregation and fibril formation of human αsynuclein: a possible molecular link between Parkinson's disease and heavy metal exposure. J Biol Chem 2001c;276, in press.
58. Uversky VN, Lee H-J, Li J, Fink AL, Lee S-J. Stabilization of partially-folded conformation during α-synuclein oligomerization in both purified and cytosolic preparations. J Biol Chem 2001d;276, in press.
59. Wakatsuki S, Hodgson KO, Eliezer D, Rice M, Hubbard S, Gillis N, Doniach S, Spann U. Small-angle-X-ray-scattering diffraction system for studies of biological and other materials at the Stanford-Synchrotron-Radiation-Laboratory. Rev Sci Instrum 1992;63:1736-40.
60. Weinreb PH, Zhen WG, Poon AW, Conway KA, Lansbury Jr, PT. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 1996;35:13709-15.
61. Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, Biere AL. Alpha-synuclein fibrillogenesis is nucleation-dependent: implications for the pathogenesis of Parkinson's disease. J Biol Chem 1999;274:19509-12.
62. Yasui M, Kihira T, Ota K. Calcium, magnesium and aluminum concentrations in Parkinson's disease. Neurotoxicology 1992;13:593-600.